NYC syringe payment program made permanent — but federal funding ban still blocks wider harm-reduction access

New York City has made permanent a pilot program that pays individuals 20 cents per returned syringe, with a daily cap of $10, as part of the city's first budget under Mayor Zohran Mamdani. The program, launched in May 2025, aims to safely dispose of syringes and reduce the risk of HIV and hepatitis C transmission among people who inject drugs. While this move represents a tangible local win for evidence-based harm reduction, it exists in the shadow of a persistent federal barrier: a long-standing appropriations rider that prohibits the Department of Health and Human Services and the Centers for Disease Control and Prevention from using federal funds to support syringe services programs, including needle exchanges. This federal funding ban remains in effect as of 2025 and has been reaffirmed in past appropriations cycles, notwithstanding CDC guidance that acknowledges SSPs reduce transmission of blood-borne pathogens without increasing drug use.

The impact of this federal restriction is starkly uneven. In states and localities with the political will and fiscal capacity—like New York City—local tax dollars can fill the gap. But in dozens of red states and rural areas, health departments lack such alternative funding, leaving injection-drug users without access to clean syringes and the wraparound services that effective SSPs typically provide, such as naloxone distribution, HIV testing, and linkage to treatment. The federal ban effectively dictates who gets to benefit from proven public health measures based on geography and state politics, contradicting the administration's stated goal of ending the overdose crisis. Repealing the rider would not only align federal policy with evidence but also likely generate net savings for the health system by averting costly HIV and hepatitis C infections. As of the source material, the administration has not proposed such a repeal.